190 related articles for article (PubMed ID: 25455899)
21. Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer.
Park JS; Kim HS; Bae YS; Cheong JH; Rha SY; Noh SH; Kim H
Jpn J Clin Oncol; 2016 Jun; 46(6):507-16. PubMed ID: 27008850
[TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1647-9. PubMed ID: 24393876
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery.
Galizia G; Lieto E; Orditura M; Castellano P; Mura AL; Imperatore V; Pinto M; Zamboli A; De Vita F; Ferraraccio F
World J Surg; 2007 Jul; 31(7):1458-68. PubMed ID: 17516110
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Carneseca EC; Serrano SV; Viana LS; Nunes JS; Martinez EZ; Santos JS
Gastric Cancer; 2014 Jan; 17(1):76-86. PubMed ID: 23455716
[TBL] [Abstract][Full Text] [Related]
25. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
PLoS One; 2016; 11(2):e0148101. PubMed ID: 26844548
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study.
Ahmed A
Libyan J Med; 2019 Dec; 14(1):1574532. PubMed ID: 30915908
[TBL] [Abstract][Full Text] [Related]
27. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.
Allgayer H; Babic R; Gruetzner KU; Tarabichi A; Schildberg FW; Heiss MM
J Clin Oncol; 2000 Jun; 18(11):2201-9. PubMed ID: 10829039
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.
Matsubara J; Yamada Y; Nakajima TE; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Oncology; 2008; 74(1-2):76-83. PubMed ID: 18544998
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.
Ishido K; Azuma M; Koizumi W; Takeuchi A; Sakuramoto S; Watanabe M; Okayasu I
Pharmacogenet Genomics; 2009 Dec; 19(12):955-64. PubMed ID: 19898266
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
31. HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.
Seo AN; Kwak Y; Kim WH; Kim DW; Kang SB; Choe G; Lee HS
Virchows Arch; 2015 Jun; 466(6):645-54. PubMed ID: 25739551
[TBL] [Abstract][Full Text] [Related]
32. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
33. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
Chung YW; Kim S; Hong JH; Lee JK; Lee NW; Lee YS; Song JY
J Gynecol Oncol; 2019 Sep; 30(5):e75. PubMed ID: 31328457
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
[TBL] [Abstract][Full Text] [Related]
36. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
37. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
38. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer.
Moghbeli M; Makhdoumi Y; Soltani Delgosha M; Aarabi A; Dadkhah E; Memar B; Abdollahi A; Abbaszadegan MR
Biol Res; 2019 Jan; 52(1):2. PubMed ID: 30621788
[TBL] [Abstract][Full Text] [Related]
39. The Role of Adjuvant Chemotherapy for Patients with Stage IB Gastric Cancer.
Toyokawa T; Ohira M; Sakurai K; Kubo N; Tanaka H; Muguruma K; Hirakawa K
Anticancer Res; 2015 Jul; 35(7):4091-7. PubMed ID: 26124360
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
